Background: The present study was done to detect Extended spectrum beta lactamase producing Klebsiella pneumoniae. Introduction: Extended spectrum of beta lactamase (ESBL) producing Klebsiella pneumoniae, frequently resistant to many of the antimicrobial agents. Antimicrobial resistance is associated with high morbidity, mortality, increased length of hospitalization and cost of health care. Materials and Methods: A total 63 Klebsiella pneumoniae strains were isolated from various clinical specimens. Out of total 63 isolates of Klebsiella pneumoniae, total 31 ESBL Positive Klebsiella pneumoniae founded. ESBL production confirmed by double disc synergy test (DDST) and by phenotypic confirmatory disc diffusion test (PCDDT). Results: Out of total 63 isolates of Klebsiella pneumoniae, total 31(49.20%) ESBL Positive Klebsiella pneumoniae founded. Highest prevalence of ESBL producing Klebsiella pneumoniae was observed in case of Pus 80.0%, followed by ET 58.3%, Wound Swab & Swab 50% each, Sputum 45.4 %, Blood 42.8%, and urine 37.5%. A total 31 ESBL Positive Klebsiella pneumoniae found in which 22 in Male and 09 in Female.
Introduction
Klebisiella pneumoniae is an opportunistic pathogen that causes various illnesses such as urinary and respiratory tract infections and septicemia. They are Gram Negative, non motile, usually encapsulated, indole and ornithine decarboxylase negative they do not produce H 2 S, produce lysine decarboxylase and http://jmscr.igmpublication.org/home/ ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i9.15 are generally positive in the Voges-Proskauer test. The size ranges from 0.3 to 1.0 mm in width and 0.6 to 6.0 mm in length 1 . Infections due to ESBL producing Klebsiella pneumoniae are of concern as third generation cephalosporins are commonly used for treatment of infections due to gram negative organisms. These infections are difficult to control as they are usually associated with resistance to aminoglycosides and cephalosporins 2 . Beta lactamases are enzymes that degrade the beta-lactam ring of the beta-lactam antibiotic group such as penicillin and cephalosporins. Extended spectrum beta -lactamase (ESBL) is an acquired class A beta-lactamase that hydrolyzes and confers resistance to oxyimino second and third generation cephalosporins e.g. cefuroxime (CXM), cefotaxime (CTX), ceftazidime (CAZ), and ceftriaxone (CTR). This is one group of beta-lactamases that is, found in certain species of Gram negative bacilli 3,4 . ESBL occur mostly among lactose fermenting members of enterobacteriaceae such as Escherichia coli, Klebsiella species, and Enterobacter species and rarely in non lactose fermenters like Pseudomonas aeruginosa. ESBLs are clinically relevant and remain an important cause of treatment failure with cephalosporins 5. Extended spectrum of beta lactamase(ESBL) producing Klebsiella Pneumoniae were first reported from Germany in 1983 and since then a steady increase in resistance against cephalosporins. Extended spectrum of beta lactamase (ESBL) producing Klebsiella pneumoniae, frequently resistant to many of the antimicrobial, show significant local variations. The majority of ESBLs are derived from the widespread plasmid mediated broad-spectrum beta-lactamase TEM-1 and SHV-1, found in Klebsiella pneumoniae and other pathogens 6 . However, in spite of their good sensitivity to beta lactam antibiotics, there are growing concerns about increasing resistance of the organism to this same class of antibiotic because of ESBL production. In this study, we will isolate Klebsiella pneumoniae from different clinical samples with detection of ESBL production by different phenotypic methods and will study the antimicrobial susceptibility pattern of ESBL producing isolates.
Materials and Methods
The prospective observational study was carried out in Department of Microbiology at National Institute of Medical Sciences & Research, Jaipur, Rajasthan. A total 63 Klebsiella pneumoniae strains were isolated from various clinical specimens of patients attending various outpatients and inpatients department at National Institute of Medical Sciences & Research. Samples including urine, body fluids, pus, sputum, swab etc. were processed for isolation and identification of Klebsiella pneumoniae within the time period of July 2018 to December 2018. All samples were inoculated on MacConkey and Blood agar, incubated at 37 • C for 24 hrs, and colonies were processed according to standard procedures. Klebsiella pneumoniae isolates that were obtained as a confluent growth from the clinical specimens were included in the study. The organisms were identified on the basis of colony morphology, Gram staining and biochemical reactions 7 . Antimicrobial Susceptibility Testing Antimicrobial susceptibility testing was performed by modified Kirby Bauer's disc diffusion method according to CLSI guidelines 2018. An inoculums with a turbidity equivalent to that of a 0.5 McFarland standard and Muller Hinton agar plates and commercially available antibiotics discs (Hi-Media, Mumbai) were used. Antimicrobial susceptibility testing was performed by modified Kirby Bauer's disc diffusion method according to CLSI guidelines 2018. An inoculums with a turbidity equivalent to that of a 0.5 McFarland standard and Muller Hinton agar plates and commercially available antibiotics discs (Hi-Media, Mumbai) were used. The antimicrobial discs were used Amikacin (30µg), Ampicillin(10 µg), Cefepime (30µg), Meropenem(10µg), Ciprofloxacin (5µg), Cefotaxime(30µg), Gentamycin(10µg), Pipracillin/Tazobactam(100/10µg) , Ceftazidime(30µg), Imipenem(10µg), Ceftriaxone(30µg), Polymyxin-B (300units) and Colistin(10µg). Results were measured and recorded as compared to that of the manufacturer interpretation charts according to the Clinical and Laboratory Standard Institute (CLSI) guideline 8 .
Screening of ESBL-Producing Klebsiella pneumoniae
According to the CLSI guidelines, isolates showing inhibition zone of ≤ 22 mm with Ceftazidime (30μg) and ≤27 mm with Cefotaxime (30 μg) and ≤25 mm for Ceftriaxone were recorded were identified as potential ESBL producers and selected for confirmation of ESBL production using disc diffusion method.
ESBL Confirmatory Tests Double Disc Synergy Test (DDST) 9
The isolated colonies were inoculated in peptone water broth at 35-37 • C for 2-6 hrs. The turbidity adjust to 0.5 McFarland's standard and lawn culture were made on Mueller-Hinton agar using sterile swab. Amoxicillin-clavulanic acid disc (20/10μg) placed in the centre of plate. Both side of Amoxicillin-clavulanic disc, a disc of cefotaxime (30μg) and ceftazidime (30μg), were placed at the distance of 15mm centre to centre from Amoxicillin-clavulanic acid disc. The plate were incubated at 37 • C overnight. Enhancement of the zone of inhibition of third generation cephalosporin toward Amoxicillin-clavulanic acid confirmed the presence of ESBL.
Phenotypic confirmatory disc diffusion test (PCDDT) test for ESBL detection 8 :
A disk of Ceftazidime (30μg) alone and a disk of Ceftazidime + Clavulanic acid (30/10μg) discs were placed at least 30 mm apart, center to center. A difference of ≥5 mm between the zone diameters of Ceftazidime and its Ceftazidime/ Clavulanic acid discs is taken to be phenotypic confirmation of ESBL production. 
Results

